Market Place
Sourcing Support
Teva’s rating cut to junk; Two Lupin facilities receive FDA warning letters
This week in Phispers, we look at the contrasting 2017 forecasts of Mylan and Teva, resulting from t
Sanofi’s rough week; Quality snags at Pfizer; FDA warns against commonly used drug
This week, Phispers delves into Pfizer’s acquisition of Medivation and its impact on Sanofi. T
